A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Uy, Geoffrey L., Mandrekar, Sumithra J., Laumann, Kristina, Marcucci, Guido, Zhao, Weiqiang, Levis, Mark J., Klepin, Heidi D., Baer, Maria R., Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J., Stock, Wendy, Sanford, Ben, Blum, William G., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2017
主題:
Myeloid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637402/
https://ncbi.nlm.nih.gov/pubmed/29034366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003053
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料